Bristol-Myers Squibb (NYSE:BMY) Shares Sold by BNP Paribas

BNP Paribas lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 63.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,362 shares of the biopharmaceutical company's stock after selling 25,101 shares during the quarter. BNP Paribas' holdings in Bristol-Myers Squibb were worth $812,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Transce3nd LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $28,000. Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $28,000. Comprehensive Financial Planning Inc. PA purchased a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $34,000. Westend Capital Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $38,000. Finally, Tacita Capital Inc purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $39,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $50.56 on Monday. The company has a market capitalization of $102.89 billion, a price-to-earnings ratio of -11.44, a PEG ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The firm has a 50-day moving average of $55.68 and a two-hundred day moving average of $56.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Bristol-Myers Squibb's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($4.40) earnings per share. As a group, analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.91%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is 92.88%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BMY shares. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Piper Sandler started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Truist Financial increased their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.09% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.